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ORAL CITRULLINE AS ARGININE
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L-Arginine may be a conditionally essential amino acid in children and adolescents with sickle
cell disease, particularly as required substrate in the arginine-nitric oxide pathway for endoge-
nous nitrovasodilation and vasoprotection. Vasoprotection by arginine is mediated partly by
nitric oxide-induced inhibition of endothelial damage and inhibition of adhesion and activation
of leukocytes. Activated leukocytes may trigger many of the complications, including vasoocclu-
sive events and intimal hyperplasias. High blood leukocyte counts during steady states in the
absence of infection are significant laboratory risk factors for adverse complications. L-Citrulline
as precursor amino acid was given orally twice daily in daily doses of approximately 0.1 g/kg
in a pilot Phase 11 clinical trial during steady states in four homozygous sickle cell disease
subjects and one sickle cell-hemoglobin C disease patient (ages 10-1 8). There soon resulted
dramatic improvements in symptoms of well-being, raised plasma arginine levels, and
reductions in high total leukocyte and high segmented neutrophil counts toward or to within
normal limits. Continued L-citrulline supplementation in compliant subjects continued to lessen
symptomatology, to maintain plasma arginine concentrations greater than control levels, and to
maintain nearly normal total leukocyte and neutrophil counts. Side effects or toxicity from
citrulline were not experienced. Oral L-citrulline may portend very useful for palliative therapy in
sickle cell disease. Placebo-controlled, long-term trials are now indicated. (J Natl Med Assoc.
2001 ;93:363-371.)
Key words: sickle cell disease * citrulline *
arginine * leukocytosis * adverse events
© 2001. From the Departments of Physiology and Medicine and the
Department of Pediatrics, Division of Hematology/Oncology and Di-
vision of Cardiology, Brody School of Medicine, East Carolina Uni-
versity, Greenville, North Carolina.
Requests for reprints should be addressed to Dr. Waugh, Depart-
ment of Physiology, Brody School of Medicine, Greenville, NC
27858. E-mail: Waughw@mail.ecu.edu
Higher than normal total leukocyte counts are
commonly present during steady states in sickle cell
disease."2 Higher total leukocyte counts in the ab-
sence of infection during steady states correlate as a
significant laboratory risk factor for adverse compli-
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cations, including painful vasoocclusive crises, strokes,
acute chest syndromes, and greater mortality rates."3`6
The high total leukocyte counts during steady
states in sickle cell anemia are primarily attributable
to increased segmented neutrophils in the periph-
eral blood; the nonsegmented (band) neutrophils
usually account for less than 4% of the total leuko-
cyte count and usually less than 7% of the total
neutrophil count.2 Increased production and use of
neutrophils are involved, in addition to a shift from
the marginal pool.7
Endothelial cells are normally quiescent, but they
can become much activated in sickle cell disease.8'9
There is endothelial damage and inflammatory vas-
culopathy.8'9 Neutrophils interact with sickle eryth-
rocytes and endothelial cells, and the neutrophils
are stimulated to release injurious substances. Neu-
trophils can produce injury to vascular endothelial
cells by a variety of mechanisms involving oxygen
products, such as superoxide, H202, and the highly
reactive hydroxyl free radical, or involving proteo-
lytic enzymes released from the neutrophils.'0 Neu-
trophils have been implicated in initiation or pro-
motion of vasoocclusive events and tissue damage in
sickle cell disease.'1 Superoxide anion, released
from endothelial cells or neutrophils, can be in-
volved in the breakdown of nitric oxide, the endo-
thelium-derived vascular relaxing factor.'2 An ade-
quate supply of L-arginine is required as a substrate
in the arginine-nitric oxide pathway by endothelial
nitric oxide synthase in its activity for homeostatic
nitrovasodilation and vasoprotection.13 Cells pro-
duce more superoxide anion generated by nitric
oxide synthase activity when cells are depleted of
L-arginine, as with ischemia or by lowered arginine
supply levels, and less nitric oxide is formed.'4
We provided evidence that a relative arginine
deficiency commonly exists in sickle cell anemia.'5
Evidence is now supplied that L-citrulline, given
orally for novel orthomolecular medical use as pre-
cursor agent for arginine biosynthesis,'6"7 results
not only in symptomatic improvement in sickle cell
disease but also in amelioration of the associated
neutrophilia.
METHODS
Selection of Patients and Study Design
The first five African-American patients who
complied with ingestion of the prescribed number
of L-citrulline capsules twice daily for 4 weeks were
studied. One of the first six subjects who had agreed
to the trial was dropped from the study because of
poor compliance without having side effects from
citrulline. Four subjects with HbSS disease were
studied: 3 males aged 14, 17, and 18 years and 1
female aged 12 years. One 10-year-old male with
HbSC disease was also studied. All patients attended
and were examined in the Regional Comprehensive
Pediatric Sickle Cell Outpatient Clinic at East Caro-
lina University. U.S. Food and Drug Administration
(FDA) and local institutional research board ap-
provals were obtained for this pilot Phase II proto-
col for L-citrulline capsules twice daily as a nutri-
tional supplement in sickle cell disease. Subjects
were enrolled after written informed consent. All
subjects had been in a steady state (not painful crisis
state) for at least 4 weeks and were not on hydroxyu-
rea therapy. On the first (control) day of each study
before citrulline was given, focused histories, physi-
cal examinations, two-dimentional echocardio-
graphic examinations, and blood specimens were
obtained. Brachial blood pressures were obtained in
the sitting position. Mean arterial blood pressures
were estimated using the formula: mean pressure
equals diastolic pressure plus one-third of pulse
pressure. Similar 4-week evaluations (post-citrul-
line) were performed at the end of the first 28-days
on citrulline. The echocardiograms were performed
in a resting state in a left lateral decubitus position,
using an Acuson Sequoia C256 imaging system
(Acuson, Siemens Co., Mountin View, CA). Total
peripheral resistances at the start and end of the
initial 4-week trials were estimated using the for-
mula: TPR units equal mean arterial pressure, in
mm Hg, divided by cardiac index, expressed in liters
of estimated left ventricular minute output divided
by square meters of estimated body surface area.
Left ventricular output in the outflow tract was es-
timated by echocardiography. The citrulline was
given orally in the morning and after the evening
meal for 28 days. Subsequent to the initial 28-day
trials in these five patients, in three of the four
patients who agreed to continue taking citrulline,
serial 4-to 6-week test periods were performed, after
at least 12 weeks of discontinued citrulline therapy.
Echocardiograms were not done during these sub-
sequent trial periods or in the fourth patient who
continuously remained on citrulline supplementa-
tion. Visual analogue scale lines were marked by
each subject during these near-monthly repeat
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clinic visits to semiquantitate the general symptom-
atic feelings of the patients' disease at that time.
Hematologic and Biochemical Measurements
Blood specimens were obtained by arm veni-
puncture. Heparinized blood samples for 1-arginine
assays were immediately put into crushed ice. Plas-
mas were separated by centrifugation at 4°C. Ali-
quots of plasma were mixed with equal volumes of
10 g/dl trichloroacetic acid solution within 45 min-
utes of venipuncture sampling. The 1:2 deprotein-
ized spun supernates of plasma were transferred
into other microcentrifuge tubes, and 0.8 molar
K2CO3 was added for neutralization. Samples were
stored frozen at -20°C before assay. Plasma i-argi-
nine was assayed by a method with absorbance dif-
ferences for monosubstituted guanidines without
and with- 5 to 6-minute incubations at 370C with
bovine liver i-arginase for specificity. l5All other
blood determinations were done by standard hospi-
tal methods.
Statistical Analysis
Paired Student's t-test for mean differences be-
tween control data (before citrulline intake) and
4-week or near-monthly data were uised. p Values
equal to or below 0.05 were considered to indicate
statistical significance.
RESULTS
All five subjects reported subjective feelings of
increased well-being dturing the first 4 weeks of each
initial or renewed 4-week or near-monthly trial pe-
riod. The senses of well-being began during the first
2 weeks. Improved sense of wellness varied from
feeling better in one sedate, studious subject to very
much better in the other 4.
As an illustration, one patient is now described
briefly. Patient AT, a 14-year-old male with sickle
cell anemia, presented initially with his usual flat
mood and appearance of lassitude before the start
of the trial. Subsequently, his mood was bright and
he reacted alertly. He said "I can breathe better"
and my pep is "better." By "breathing better," he
meant that he did not get short of breath as quickly
as he had done in the past with normal physical
activity. He also reported "I have more energy and
stay awake better." "My grades are better because
I'm awake and study more." He said that he can run
better and play basketball better without tiring as
much compared to before the intake of the capsules
(of citrulline). No adverse effects or painful epi-
sodes were experienced during the periods of the
trial while on citrulline.
Table 1 illustrates the individual general symp-
toms of illness or sense of well-being, and the indi-
vidual and average values of cardiovascular param-
eters found before and during or 1 day after the
initial 28-day period of citrulline supplementation.
The L-citrulline was prescribed twice daily in daily
dosages of 0.09 to 0.13 g/kg during this initial trial
period. There were no significant mean changes in
measured mean arterial blood pressure, heart rate,
left ventricular mass index (LVMI), cardiac output,
cardiac index, or total peripheral resistance in the
five patients. The initial high cardiac outputs and
cardiac indices in the sickle cell anemic subjects
remained higher than normal in the 4 HbSS pa-
tients. However, in one of these patients, case pa-
tient AT, much cardiomegaly was initially evident,
with a striking reductiotn in measured left ventricu-
lar end-diastolic dimension from 5.2 to 4.8 cm (not
tabulated) and a dramnatic reduction in LVMI from
116 to 81 g/M2 over the 28-day interval. Sizable
reductions in his cardiac index of 19% and in his
mean arterial blood pressure of 26% were associ-
ated, with only modest redcuction in total peripheral
resistance (see Table 1). This was in one of the four
subjects who experienced much less exertional dys-
pnea and exertional fatigue while on the citrulline
supplementation. All four patients with HbSS dis-
ease had measured decreases in LVMI in this initial
4-week trial, but the mean paired decrease was not
of statistical significance. Cardiac output and car-
diac index were within normal limits in the younger
patient with HbSC disease (patient SH). No symp-
toms of light-headedness or episodes of syncope
were reported by any of the patients while they were
receiving citrulline.
There were significantly mean decreases in total
leukocyte counts and segmented neutrophil counts
in the five patients during their initial 4-week trials
on citrulline. Results are tabulated in Table 2, in
which the mean decrease was from 12.46 + 1.81 to
9.99 + 1.70 k/,uL in total leukocyte count and
6.39 ± 1.44 to 4.18 ± 1.23 k/,uL in segmented
neutrophil count, with p-values of <0.001 and
<0.005, respectively. Table 2 also shows that the
citrulline supplementation was not associated with
statistical significant mean changes in the degree of
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Table 1. Symptoms of Illness and Cardiovascular Measurements Before and During or 1 Day After the Initial 4-Week
Trials of L-Citrulline
Symptoms MAP HR LVMlt CO Cl TPR
Variable Time (U, B, VMB) (mm Hg) (beats/min) (g/m2) (L/min) (CO/M2) (units)
1AT; Before U 97 85 116 6.88 4.41 22.0
HbSS After VMB 72 62 81 5.55 3.56 20.2
2JF; Before U 91 70 73 5.67 3.34 27.2
HbSS After B 74 79 69 6.13 3.57 20.7
3AF; Before U 77 83 86 7.57 3.77 20.4
HbSS After VMB 96 82 81 10.50 5.36 17.9
4TD; Before U 63 96 78 7.98 4.63 13.6
HbSS After VMB 90 64 67 6.10 3.47 25.9
5SH; Before U 73 73 45 2.43 2.36 30.9
HbSC After VMB 74 67 58 2.21 2.16 34.2
Mean + SEM Before 80 ± 6.1 81 + 5 80 ± 11 6.1 ± 1.0 3.7 ± 0.4 22.8 + 3.0
Mean SEM After 81 + 4.9 71 + 4 71 ± 4.4* 6.1 ± 1.3 3.6 0.5 23.8 ± 2.9
*U, B, and VMB represent the general feelings of illness by the patient as usual, better, or very much better. MAP, mean
arterial pressure; HR, heart rate; LVMI, left ventricular mass index estimate per body surface area; CO, cardiac output; Cl,
cardiac index; TPR, total peripheral resistance. SEM represents standard error of the mean.
tp-value < 0.10 for mean paired decrease of 13.9 + 7.2 g/m2 in LVMI (1-sided t-test) in the 4 HbSS subjects.
hemolytic anemias, because mean hemoglobin, re-
ticulocyte, and serum bilirubin values were similar
before and at the end of the trial periods. Values for
mean red cell volume, mean cell hemoglobin, and
mean cell hemoglobin concentration were not ap-
parently influenced by citrulline administration
also, as shown in Table 2. However, with citrulline,
plasma arginine concentration rose sizably in four
of the subjects, but not in the fifth patient with the
greatest magnitude of reticulocytosis and hyperbil-
irubinemia (patient AF). Mean plasma arginine
level rose from 77 ± 9.1 to 127 + 18 ptmol/L, with
a p-value of <0.05. This represented a 65% mean
increase in plasma arginine concentration from the
initial mean value.
With continuous tL-citrulline supplementation in
two of the HbSS patients over 5 near-monthly inter-
vals and in one of the patients with HbSS disease
over 9 near-monthly periods, Table 3 documents
that mean total leukocyte counts and segmented
neutrophil counts continued lower than found in
these three individuals before their initial control
time states. In the patient with HbSC disease, these
white cell parameters remained lower than in the
three HbSS subjects. Mean visual analog scale line
values for well-being or sense of illness at the end of
the near-monthly periods remained very much
lower than the control before values for each of the
four patients (see Table 3). Mean plasma arginine
levels were elevated sizably and up to 2.9 times
higher than the control before levels in three of the
patients. Meani arginine level was found to be barely
raised in patient AF with the greatest magnitude of
hemolytic anemia, as was similarly found in the
initial near-monthly (28-day) period shown in Table
2 for the same patient, AF.
Only one patient experienced a severe painful
vasoocclusive crisis during the above near-monthly
periods. This patient, TD, wNras hospitalized for
acute, multiple somatic pains and acute chest syn-
drome during 1 of her 5 near-monthly continuous
trial periods. Upon hospitalization for this acute
crisis, her total leukocyte count was very elevated to
24.9 k/,uL, her segmented neutrophil count was
very high at 20.42 k/,uL, and her plasma arginine
level was found much lower than before, at 48
,umol/L. Citrulline supplementation was given un-
der supervision during her hospitalization at her
usually prescribed, prehospital daily doses of 3 g in
the morning and 4 g at night without untoward
results. Near the end of her hospital stay (for 9 days)
with conventional concurrent therapy, her total leu-
kocyte coUlnt had declined to 12,500 k/,tL and her
plasma argininie concentration was much higher at
201 ,umol/L.
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Table 3. Visual Analog Scale Values of Illness, Leukocyte Counts, Hemoglobin Values, and Plasma Arginine Levels
Before Initiation and at the End of Continued Near-Monthly Periods While on Continuous L-Citrulline Supplementation
No. of VAS WBC* NEUTR HB ARG
Variable periods (0 to 5) (k/guL) (k/pLL) (g/dL) (I.Mol/L)
AT; Before 5 2.5 9.10 5.46 9.1 69
HbSS Mean ± SEM 0.21 ± 0.09 8.27 ± 0.80 3.10 ± 0.68 9.0 ± 0.1 201 ± 26
AF; Before 9 2.5 18.00 12.06 7.8 71
HbSS Mean ± SEM 0.6 ± 0.6 15.31 ± 0.76 8.55 ± 0.51 7.1 ± 0.1 81 ± 7.9
TD; Before 5 2.5 24.70 11.85 7.5 81
HbSS Mean ± SEM 1.0 ± 1.0t 13.94 ± 1.38 7.04 ± 1.13 7.8 ± 0.2 175 ± 36
SH; Before 5 2.5 5.31 3.08 10.2 118
HbSC Mean ± SEM 0.1 ± 0.1 6.83 ± 0.94t 3.97 ± 0.80 10.8 ± 0.2 162 ± 18
*VAS represents visual analog scale line values of general feelings of illness by each patient in each period of 4 to 6
weeks, based on 0 for very good, 2.5 for prior usual degree of illness, and 5 for very bad. WBC, total leukocyte count;
NEUTR, segmented neutrophI count; HB, hemoglobin; ARG, arginine.
tHospitalized for several days with one acute chest syndrome crisis during one period when WBC rose to 24.9 k/,Ll and
plasma arginine level was found to be low at 48 ,umol/L.
tThis patient had one episode of acute upper respiratory tract infection with WBC elevation to 10.3 k/,tl at the end of
one of the 5 period intervals.
DISCUSSION
It is problematic as to the mechanisms by which
the ingestion of L-citrulline twice daily resulted in
remarkable symptomatic improvements in these five
patients with steady-state sickle cell disease. Al-
though we cannot rule out the placebo effect, the
considerable change in each patient's symptoms
suggests more than a simple placebo effect. None of
the five patients had contact with another patient
receiving citrulline during the initial five sets of
28-day trial periods. In addition, in the subsequent
four patient sets of continuous trial periods with
supplementation, visual linear analog scale values,
self-administered by the four patients at the end of
each near-monthly period, showed that they main-
tained much improvement in feelings of well-being.
This appears to confirm the presence of more than
a simple placebo effect with citrulline intake. Visual
linear analog scale values have been shown to be
reliable in subject self-assessment for evaluating
well-being and pain under various conditions.'8 Pa-
tient self-assessment analog scale scores have been
used successfully before for well-being and pain in
patients with sickle cell disease.'9'20
The remarkable lessening of exertional fatigue
and lessening of exertional dyspnea associated with
sizeable improvement in left ventricular end-dia-
stolic dimension from 5.2 to 4.8 cm (data not tabu-
lated) and in a large reduction in left ventricular
mass index (LVMI) of 25 g/m2 in the patient, AT,
over the initial 28-day interval with citrulline,
strongly suggests that compensated cardiac func-
tional impairment was present initially in this pa-
tient, which lessened with citrulline intake. In all
four patients with HbSS disease, LVMI decreased
somewhat with the initial 28-day course of citrulline
(p-value < 0.10) (see Table 1).
In patient AT, there occurred measurable reduc-
tions in the high mean arterial blood pressure and
resting high cardiac index towards a normal and
more nearly normal value, respectively, with low-
ered peripheral vascular resistance (Table 1) at the
end of the 28-day interval. These associations appar-
ently indicate that a systemic vasodilator, antihyper-
tensive effect was operational with the citrulline sup-
plementation. Similarly, the other subjects may have
had improved cardiac performance and systemic
capillary nutrient perfusion performance with exer-
cise. This may have been responsible for their less-
ening of exertional fatigue and improved sense of
well-being and sense of more energy while on cit-
rulline intake. Cardiomegaly and ventricular dia-
stolic abnormalities are commonly early features in
sickle cell anemia even without overt symptoms of
decompensated heart failure or hypertension.2b-25
Contributions from blood flow shunting with ar-
teriovenous bypassing of certain systemic capillary
vascular beds is present in the steady state of sickle
368 JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION VOL. 93, NO. 10, OCTOBER 2001
CITRULLINE TRIAL IN SICKLE CELL DISEASE
cell disease.26'27 Such shunting with reduced cardiac
afterloads are said to account for the increased rest-
ing cardiac outputs and cardiac indices found typi-
cally in sickle cell anemia disproportionate to the
degree of anemia.2628 Unusually high indices also
were found in our four subjects with sickle cell
anemia (see Table 1).
Lonsdorfer et al.28 showed that sickle cell anemia
subjects in steady states are chronically maintained
at the upper limit of physiological compensatory
mechanisms with high systemic vasodilator activity
when they are not in painful crises. Nitrate forma-
tion as an index of nitric oxide production is also
increased in steady-state sickle cell disease.29 It had
been speculated by Waugh et al.'5 that the effective
compensatory reduced after-load mechanisms in-
clude overactivity of the endogenous endothelial
arginine-nitric oxide system.'3 This process may
need to be maintained by a continuous supply of
arginine as available plasma substrate for nutrient
capillary flow and to avoid or lessen vasoocclusive
crises.'4'5 With sufficient available plasma arginine
for sufficient activity of endothelial nitric oxide syn-
thase in producing vasoprotective nitric oxide as
product, proinflammatory cytokines and adhesion
molecules by the endothelium and leukocytes will
be suppressed, as suggested by previous studies.30
Exogenous sources for formation of nitric oxide can
limit the degree of endothelial activation and leu-
kocyte adhesion.30 Cytokines such as tumor necrosis
factor a and endothelin-I are sometimes high in
peripheral plasma in steady-state sickle cell dis-
ease.31-33 Increased expression of proinflammatory
cytokines may be manifested by significant fatigue.34
Increasing evidence indicates that neutrophils are
activated and play an important role in the initia-
tion and propagation of vasoocclusive processes in
sickle cell disease."1'35
There is much increased active bone marrow ex-
pansion with increased hematopoietic activity in
sickle cell anemia, with increased vascularity and
arteriovenous shunting of blood.2",36 There is much
increased bone marrow blood flow in sickle cell
anemia.37 The expanded bone marrow vascularity
with increased hematopoiesis, as judged by in-
creased reticulocytosis (see Table 2), may have ac-
counted partly for the increased cardiac outputs
and cardiac indices that were maintained during
supplementation in the four patients studied with
sickle cell anemia (Table 1). However, increased
nutrient capillary perfusion and lessening of arte-
riovenous shunting in various parts of the body may
have resulted because of improvement in the endo-
thelial arginine-nitric oxide pathway.
The elevated cardiac outputs and cardiac indices
typical of sickle cell anemia in the steady state may
be considered analogous to the increased cardiac
outputs and cardiac indices found in advanced
Paget's disease of bone. When the hyperemic bone
disease is generalized, Paget's bone disease is asso-
ciated with blood being shunted through the af-
fected bones.38 Cardiac hyperkinesis analogous to
that found with open arteriovenous communica-
tions results.38 In sickle cell disease, sufficient activ-
ity of the constitutive endothelial L-arginine-nitric
oxide pathway in bone marrow may be necessary to
maintain bone marrow nutrient capillary blood flow
without much stasis and vasoocclusive events. This
trial with citrulline as arginine precursor suggests
that citrulline supplementation may tend to prevent
painful bone crises in sickle cell disease.
Increased plasma hemoglobin levels, which tend
to vary with the degree of hemolysis in sickle cell
disease, tend to correlate inversely with plasma ar-
ginine levels in sickle cell anemia, because of argi-
nase being liberated from red cells in vivo when
they are hemolyzed.'5 This may underlie the failure
to elevate plasma arginine levels to much higher
levels than control values with the amounts of cit-
rulline used in our 1 patient with the greatest de-
gree of reticulocytosis and hyperbilirubinemia, pa-
tient AF (see Table 2). Free hemoglobin in
circulating plasma is also a very avid scavenger of
formed nitric oxide as endothelium-derived vascu-
lar relaxing factor.39 It is indeed relevant that inhi-
bition of the usual activity of endothelial nitric ox-
ide synthase enzyme leads to cerebrovascular
adherence of human sickle red cells and vasoocclu-
sive strokes when sickle red cells are injected in a rat
model.40
This study showed that L-citrulline supplementa-
tion in patients with sickle cell disease reduced high
total leukocyte counts and segmented neutrophil
counts towards or to normal counts. Associated was
symptomatic improvement in the patients. Admin-
istered orally, L-citrulline is an efficient precursor
for the endogenous biosynthesis of L-arginine.16,17'41
L-Arginine and formed nitric oxide participates im-
portantly in the homeostatic control of the vascula-
ture, is vasoprotective normally, inhibits cytokine
formation and myointimal hyperplasias, and is in-
volved in immunity.13'42
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Therefore, further investigation of the likely ben-
eficial effects of L-citrulline supplementation in
sickle cell disease appears warranted using placebo-
controlled studies. Citrulline may be synergistic
even to the use of hydroxyurea in sickle cell disease.
This drug appears to have part of its beneficial
therapeutic effect due to myelosuppressive effects
on peripheral total leukocyte and neutrophil
counts.6,43
Citrulline therapy has been nontoxic, even in
quite large doses of 5.7 g daily given chronically to
a 4-year-old child with a dibasic amino acid defect.44
It may be safe to administer citrulline even in the
presence of infection or sepsis in sickle cell dis-
ease.4546 With infection or sepsis, there is lack of
significant expression of activity of inducible nitric
oxide synthase away from the nidus of infection.46 It
is believed that citrulline supplementation for pal-
liation may eventually be shown to improve the
quality of life in many thousands of African Ameri-
cans suffering from serious sickle cell disease.
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